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1. Introduction
Endoscopic resection of colorectal polyps is a well-recognised therapy for the prevention of
colorectal carcinoma. Roughly 10% of resected polyps contain foci of carcinoma and are of‐
ten termed malignant polyps or polyp cancers. Their incidence is increasing in line with the
increasing use of colonoscopy.[1] A proportion of these will have progressed to nodal dis‐
ease before presentation and a further oncological resection should be considered for high
risk patients.[2]
The risk of nodal disease at presentation can be stratified by histology but definitive staging
information can currently only be obtained by oncological resection, a procedure which can
cause significant morbidity and mortality, especially in the elderly. This is of particular rele‐
vance as the majority of patients do not have nodal disease, even for the most dangerous
categories of polyp.[3] There is a real risk of causing excess morbidity by over treating the
majority in order to adequately treat the minority.
2. Malignant polyps
Not all polyps are created equal. The adenoma carcinoma sequence has long been recog‐
nised as the natural history of colorectal carcinoma and it is therefore logical that some ade‐
nomas will be discovered with foci of malignancy within them.
For those confined to the mucosa, polyps showing foci of potentially malignant cells are of‐
ten termed carcinoma in situ. The lack of lymphatics in the mucosa prevents distant spread
and, as these lesions are neither regarded as malignant or treated as malignancies, the term
high grade mucosal neoplasm is now preferred. [4]
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The definition of colorectal carcinoma is dysplasia crossing the muscularis mucosa, so when
high grade dysplasia in these polyps crosses this barrier the lesion is termed a malignant
polyp. A malignant polyp is essentially a macroscopically benign lesion that contains malig‐
nant foci on further examination. When the totality of the polyp is comprised of malignancy
the term polypoid carcinoma is often used.
T1 lesions are therapeutically significant as they are the first lesions where nodal and distant
metastases must be considered. The management of these polyps is based on the belief that
the risk of spread can be stratified according to the histology of the resected polyp.[5] In the
past authors used various criteria to define favourable or unfavourable histology and guide
management.[1,2,6,7] For a large part, this has involved dividing patients into two groups.
A “low risk” group, who are safe without further treatment and a “high risk group”, for
whom surgery should be considered.[8,9] Unfortunately published studies disagree about
the factors that are most significant.[3,10-12]
3. Factors affecting risk of nodal disease
3.1. Morphology
The Paris classification[13] of gastro-intestinal tumours recognises that adenomas may be
polypoid or non polypoid. Non polypoid (0-II, 0-III ) lesions are not usually removed endo‐
scopically as they are more challenging to remove and are recognised to have high malig‐
nant potential.
0-I: Polypoid 0-Ip: Pedunculated
0-Is: Sessile
0-II : Non-Polypoid, Non Ulcerated 0-IIa: Slightly elevated
0-IIb: Flat
0-IIc: Slightly depressed
0-III: Ulcerated
Table 1. Paris Classification of Superficial Tumours of the Colon and Rectum.[13]
Polypoid lesions can be pedunculated (Type 0-1p) or sessile (Type 0-1s). Due to their shape
malignant sessile polyps are harder to remove with clear margins and have more ready ac‐
cess to the deeper portions of the submucosa. They are therefore more likely to be classified
as high risk. Seitz et al[9] presented a series of 114 endoscopically removed malignant pol‐
yps. Overall 46% of these polyps were sessile, but 65% of “high risk” (ie. requiring surgical
removal) polyps were sessile. Conversely only 23% of “low risk” polyps were sessile.
An earlier literature series of 741 malignant polyps reported that 58.3% of sessile polyps had
“high risk features” (Grade 3-4, vascular or lymphatic invasion, positive resection margin)
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whereas only 10% of pedunculated polyps were similarly classified.[11] One meta-analysis
reported positive resection margins in 56.8% of sessile lesions verses 18.7% in polypoid le‐
sions (P < 0.0001).
Size and tubular or villous architecture are also well known to affect the malignant potential
of polyps. However, in a similar fashion to flat or depressed areas of dysplasia, very large
polyps are seldom excised endoscopically and are not relevant to the current topic.
3.2. Grading
Polyps are defined by dysplasia and the varying degree displayed by different polyps is
thought to explain a large degree of their different metastatic potential.[14]
Negative for Intraepithelial neoplasia.
Indefinite for Intraepithelial neoplasia.
Low-grade Intraepithelial neoplasia. Adenoma/dysplasia
High-grade neoplasia (intraepithelial or intramucosal) Adenoma/dysplasia (4-1
Noninvasive carcinoma (4-2)
Suspicious for invasive carcinoma (4-3)
Intramucosal carcinoma (lamina propria invasion) (4-4)
Submucosal carcinoma
Table 2. Revised Vienna classification of epithelial neoplasla for esophagus, stomach, and colon. [13]
The revised Vienna classification is widely used to define the degree of dysplasia colorectal
polyp. By definition malignant polyps are 4-4. For colorectal carcinomas the WHO classifica‐
tion recognises 4 grades of differentiation, with G1 representing well differentiated, through
moderate (G2) and poorly differentiated (G3) to undifferentiated (G4). G1-2 are convention‐
ally regarded as low grade and G3-4 as high grade.
In a meta-analysis of published series, Hassan et al.[1] reported a 3.9 (1.9-8.4) odds ratio for no‐
dal metastasis with regard to high vs low grade malignant polyps. The odds ratio for mortality
was reported as 9.2 (4.7-18.2). Determining the exact risk from high grade dysplasia is compli‐
cated by their relative rarity. One study of 80 malignant polyps found only 2 poorly differenti‐
ated polyps.[12] In a meta-analysis 7.2% of 1612 malignant polys were high grade.[1]
It is interesting to note that despite poor differentiation being recognised as an important
determinant of nodal disease, no universally accepted definition exists. Indeed in studies
where the prevalence of highly dysplastic lesions was lower, the risk of nodal disease in
these polyps was increased. (See Table 3). This suggests that poor differentiation, when a
rigorous definition is used is an extremely important predictor of nodal disease. Those stud‐
ies that did not find the degree of dysplasia to be significant are hampered by the very small
number of highly dysplastic lesions in their sample.
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Study Number Of T1 Tumours Incidence of G3 Poorly
Differentiated/%
(No. of Cases)
Incidence of Nodal
Involvement /
% (No. of Cases)
Yamamoto et al 2004 301 0.1 (4) -
Tominaga et al 2005 155 1.3 (2) 50.0 (1)
Kurokawa et al 2005 180 1.1 (2) 50.0 (1)
Whitlow et al 1997 59 1.7 (1) 0 (0)
Haggitt et al 1985 64 3.1 (2) 0 (0)
Geraghty et al 1991 81 2.5 (2) -
Suzuki et al 2003 65 3.1 (2) 100 (2)
Sakuragi et al 2003 278 2.5 (7) 57.1 (4)
Seitz et al 2004 116 3.4 (4) -
Wang et al 2005 159 4.4 (7) 85.7 (6)
Morson et al 1984 61 5 (3) -
Cooper et al 1995 140 5.7 (8) -
Netzer et al 1998 62 8.1 (5) 40.0 (2)
Hackelsberger et al 1995 87 11.5 (10) -
Hassan et al 2005 380 14.7 (56) 23.2 (13)
Nascimbeni et al 2002 344 34.0 (117) -
Nascimbeni et al 2004 144 39.6 (57) -
Table 3. Incidence of G3 Poorly Differentiated T1 Colorectal Carcinoma and Incidence of Nodal Involvement. In those
studied with a higher incidence of G3 carcinoma, incidence of nodal disease in those carcinomas falls. From[3]
3.3. Depth of invasion
Haggitt’s classification is based on the greatest anatomical depth of invasion in pedunculat‐
ed polyps.[5] Haggitt 0 lesions are confined to the mucosa. Haggitt grades 1-3 breach the
submucosa within the polyp, and they are confined to the head, neck and stalk of the polyp
respectively. Only Haggitt 4 lesions invade past the stalk into the submucosa of the wall.
Most authors would agree that only Haggit 4 lesions require further treatment. If adequately
excised, Haggitt 0-3 lesions have a risk of recurrence (<1%) which is lower than the predict‐
ed mortality of an oncological resection.[15,16] Conversely, for level 4 lessions, Haggitt re‐
ported nodal disease rates of almost 13%.
All sessile lesions are Haggitt 4 by definition, but other authors have treated selected sessile
lesions with polypectomy alone to good effect. Kudo produced a refinement for sessile pol‐
yps by dividing the submucosa into thirds.[13] This has become known as the Kikuchi clas‐
sification. [2] Lesions confined to the superficial third of the submucosa (called Sm1)
demonstrated very low rates of nodal disease and many authors recommend no further
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treatment after polypectomy for Sm1. In the absence of other risk factors most would agree
for Sm2 lesions as well.[7]
The Kikuchi classification has been widely accepted for the assessment of T1 colorectal tu‐
mours but can be difficult to perform on endoscopy specimens as the muscularis propria is
not usually included in the specimen.[2]
Difficulty is also encountered when the muscularis muscosa cannot be identified. A large col‐
laborative Japanese study used Haggit level 2 (i.e. the border between the head and neck of
the polyp) as a baseline for pedunculated polyps. Provided that there was no lymphatic in‐
vasion, they found no nodal disease if the depth of invasion from here was <3mm. For ses‐
sile polyps the superficial aspect of the lesion was used and again no nodal disease
discovered if the invasion was <1mm, regardless of other lymphatic invasion. [17] Other Jap‐
anese studies have also found good correlation between quantitative measures of submucos‐
al invasion and risk of lymph node metastasis.[18,19]
Although the study included operative specimens as well as endocsopically removed malig‐
nant polyps, Ueno[14] showed that the width of tumour invasion is also an important factor.
3.4. Incomplete or piecemeal resection
Involved resection margins have been shown to be strongly associated with poor outcomes.
These patients have higher mortality, local recurrence and rates of residual disease. In one,
all be it small, study 75% of incompletely resected polyps were associated with an adverse
outcome.[20] It should be noted that even when incomplete resection is reported, absence of
residual disease in the surgical specimen is the rule (94% in one study) rather than the ex‐
ception[21]. This is likely due to diathermy electrofulguration of the remnant.
The European recommendations state that tumour cells within 1mm of the margin repre‐
sents a positive margin[22], with some authors arguing then >2mm represents the true safe
margin[21].
Incomplete removal is failure of primary therapy and requires further resection. Piecemeal
removal of the polyp prevents proper histological assessment and surgery is mandated in all
cases. For this reason endoscopic mucosal resection by the strip biopsy method is discour‐
aged for the removal of potentially malignant lesions.
3.5. Lymphatic and vascular invasion
Lymphatic invasion has been sighted by some authors as an important predictor of nodal
disease. Controversy exists however as reported cases are rare and usually associated with
poorly differentiated tumours or incomplete resection. Inter-observer variability and the
ease of mistaking retraction artefact for lymphatic invasion also make interpretation diffi‐
cult.[6,12]
Lymphatic invasion is usually associated with other high risk factors and in those cases with
adverse outcomes, almost invariably so. Many authors would regard its status as an inde‐
pendent risk factor is unclear.[20] However a large multi-centre retrospective study from Ja‐
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pan found lymphatic involvement to be highly significant for nodal metastases (odds ratio
4.69 P<0.0001) in a multivariate analysis of risk factors.[17] They also found that in a small
number of cases adverse outcomes were seen from cases of lymphatic invasion, despite in‐
vasion being confined to the head of the polyp (Haggit 1).
Vascular invasion is also considered difficult to identify, but where present, it is strongly as‐
sociated with nodal disease. Yasuda[18] studied T1 rectal tumours, including specimens
from primary resections and resections after polypectomy. The odds ratio for the nodal
metastasis with reference to the presence or absence of vascular invasion was 12.023 (3.751–
116.751 p=0.001). Another study of sessile T1 colorectal carcinomas found that vascular inva‐
sion was a significant factor in both univariate and multivariate analysis. However they ad‐
mit that the small number of cases of vascular invasion were found in lesions with deeper
Sm3 invasion.[23]
An odds ratio of 7 (2.6–19.2) for lymph node metastasis was reported in the only meta-anal‐
ysis looking specifically at malignant polyps and the presence of vascular invasion.[1] How‐
ever, the same analysis demonstrated no such increased risk in polyps that would otherwise
be considered low risk. It may well be that vascular invasion carries no special significance
in itself and should not be emphasised in decision making.
3.6. Tumour budding
Tumour budding is the presence of microscopic islands of tumour cells out ahead of the
main front of tumour invasion. At present there is no defined agree standard to reporting
the phenomenon but several authors have found it to be highly significant. Yasuda reported
an odds ratio of 11.11 (3.64–146.03)[18] for predicting nodal disease but until further study
occurs it is difficult to make firm recommendations.
3.7. Location
T1 rectal tumours seem to be particularly likely to cause nodal disease, especially when lo‐
cated in the lower third.[15,23] However at this stage there have been no studies looking at
this relationship specifically in malignant polyps.
4. “The low risk polyp”
Several authors, starting with Morson in 1984[24], have developed the concept of the low
risk polyp. That is, a polyp which can be safely treated with polypectomy alone, as there is
minimal risk of nodal disease. The concept has been incorporated into the American College
of Gastroenterology guide lines[25]. They recommend no further treatment if:
The polyp is considered to be completely excised by the endoscopist and is submitted in toto
for pathological examination.
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In the pathology laboratory, the polyp is fixed and sectioned so that it is possible to accurate‐
ly determine the depth of invasion, grade of differentiation, and completeness of excision of
the carcinoma.
The cancer is not poorly differentiated.
There is no vascular or lymphatic involvement.
The margin of excision is not involved. Invasion of the stalk of a pedunculated polyp, by
itself, is not an unfavourable prognostic finding, as long as the cancer does not extend to the
margin of stalk resection.
The European recommendations, while noting the potential of tumour budding and lym‐
phatic and vascular invasion as prognostic factors, decline to provide a guideline as they
have not been statistically significant in all cases.[22]
Another perspective is given by Nicholls,[7] who instead offered an algorithmic approach.
He differentiates between colonic and rectal polyps. For rectal lesions judged to be adenoma
prior to resection he recommends that all poorly differentiated lesions be removed. For co‐
lonic polyps he suggested further resection solely for Haggit 4 polyps (including by defini‐
tion all sessile polyps) with a depth of invasion >1000 µm.
Systematic review of studies which selected low risk polyps using methodology broadly
similar to the American criteria has demonstrated very low rates of nodal recurrence. (See
Table 4). Mortality from oncological resection varies greatly by age and co-morbidity but is
usually quoted around 3-5%.[26-28] Therefore, for these lesions, the safest course of action is
surveillance rather than further resection.[8,29]
It should be noted that these criteria take no account of the depth of invasion and that these
guidelines would encourage the removal of some lesions that have been safely treated by
endoscopy. It may be that they are documenting many of the same characteristics but in a
different way. It is not hard to imagine that Sm3 lesions are less likely to be excised with
clear margins and are more likely to show poor differentiation. Indeed a large study of sur‐
gically resected sessile T1 colorectal tumours found Sm3 invasion in 68% of G3+4 tumours
and on 33% in G1+2 (P=0.001). This study also found tumour grade not to be significant on
multivariate analysis.[23]
Given Japanese experience it maybe be better to refine the criteria for a low risk polyp as
any polyp lacking all of these features:
High grade (G3-4) lesions.
Incomplete resection or other factors preventing adequate histological assessment of the le‐
sion.
Piecemeal resection
Depth of invasion greater than 2mm from muscularis mucosa
Width of invasion greater than 4mm.
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The utility of including lymphatic invasion, vascular invasion or tumour budding is unclear
at this time. Further work should be done to examine the risk from polyps of the lower third
of the rectum, especially as these can often require a permanent stoma if oncological resec‐
tion is performed.
Study No. Of Polyps UnfavourableOutcome
Unfavourable outcome in low
risk group
Bernard et al. 1988 19 3 0
Christie 1988 88 6 0
Conte et al. 1987 30 4 0
Cooper et al. 1995 140 16 0
Cranley et al. 1986 39 10 0
Cunningham et al. 1994 36 2 0
Eckardt et al. 1988 61 11 0
Fried et al. 1984 22 0 0
Geraghty et al. 1991 80 5 0
Hackelsberger et al. 1995 86 8 0
Kikuchi et al. 1995 78 9 0
Kyzer et al. 1992 42 1 0
Morson et al. 1984 60 2 0
Netzer et al. 1998 70 16 0
Rossini et al. 1988 66 4 0
Shatney et al. 1975 28 1 0
Speroni et al. 1988 30 2 0
Sugihara et al. 1989 25 3 0
Volk et al. 1995 47 10 0
Whitlow et al. 1997 59 4 0
Seitz et al. 2004 114 16 0
Total 1,227 135 0
Table 4. Incidence of Adverse Outcome in Low Risk Polyps. Low risk = Low risk = excision complete with resection
margins of at least 2 mm, no Grade 3 carcinoma, and no vascular invasion. (From Sitz et al. 2004)
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5. “The high risk polyp”
Polyps that do not meet the low risk criteria should be considered for surgical removal even
if there has been total excision of the primary lesion. Indeed, it is unusual to find residual
tumour in the surgical specimen, especially if the lesion had clear histological margins.[6]
The justification for surgery is the desire for regional control as the risk of nodal disease is
much higher in these patients and oncological resection is required to obtain regional con‐
trol in a similar manner to other colorectal malignancies. The dilemma is that only a minori‐
ty of these patients have nodal disease requiring control and these patients are only reliably
identified after resection. Especially in elderly, the decision to resect has the possibility to
cause considerable harm without producing a benefit to the patient.
5.1. “First do no harm...”
It is an old surgical adage that surgery is only indicated if the natural history of the cure is
better than the natural history of the disease. In situations of uncertainly like this it is useful
to examine the possible outcomes of proposed courses of action in order to see were the sur‐
vival advantage lies.
The outcomes of the decision to operate will be a function of the risk of nodal disease and
the risk of operative mortality and morbidity. We feel it is useful to consider these decisions
with reference to a 2x2 table of results
Nodal disease
Yes No
Further
Resection
Yes Survival similar to resested Stage IIIadisease (roughly 75%) Operative mortality (Variable)
No Survival as for stage IV disease (Roughly5%)
Curative procedure, without operative mortality
(Roughly 100%)
Table 5. 2x2 Table of outcomes from the decision regarding further resection of high risk malignant polyps.
5.2. Nodal disease and oncological resection
We see no reason to regard these patients as any different from patients who had proceded
straight to oncological resection and post operatively were staged either IIIa to IIIc (TNM
v5). In the SEER data from 1998 to 2000 there is a huge difference between those with regard
to five year survival (73% vs. 28% respectively). Clearly this stage differentiation has huge
implications for the advisability of surgery. It has been suggested that T1-2N2 tumours have
a better survival that T3-4N2 tumours and the TNMv6 classification has been changed to re‐
flect this. Newer SEER data shows five year survival of 87.7% for T1-2N1 disease and 75%
for T1-2N2 disease. [30]
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To our knowledge there is no current method of estimating the extent of nodal disease from
polypectomy histology.
5.3. Nodal disease and no further resection
For those patients with nodal disease who do not have it resected the prognosis is likely to
be compromised. Intensive surveillance is likely to detect continued disease progression.
The role of chemotherapy and or radiotherapy has not been clearly defined in this group but
is likely to be palliative in nature.
5.4. Absence of Nodal disease
The survival of patients after endoscopic removal of T1 lesions and no nodal disease is ex‐
cellent. The mortality in these groups will be limited to the operative mortality from further
resection.
5.5. Risk of Nodal disease
Various figures have been quoted in the text for the risk of nodal disease in high risk pa‐
tients. This can partly be explained by the differing criteria used to define risk by various
authors. Further stratification within the “high risk group” may become apparent with fur‐
ther study.
The St Mark’s Lymph Node Positivity Model[31] can be used to predict the individual risk
of nodal metastasis after local resection of rectal tumours. However it makes no distinction
within T1 tumours. Such assessment of individual risk factors to produce a personalised risk
is not possible based on the current evidence. Further studies using multivariate analysis
will be required to tease out the importance of individual risk factors.
For our analysis we have chosen to present data based on Sm depth as this has shown to be
a reproducible predictor of nodal disease. Both Kikuchi and Nascimbeni reported rates of
roughly 5, 10 and 25% for Sm 1, 2 and 3 respectively.[23,32]
Risk Factor Incidence of nodal disease
Depth of invasion Haggit 1.2.3 = <1%[9]
Kikuchi SM1 = 5%
Kikuchi Sm2 = 10%
Kicuchi Sm3 = 25%[23, 32]
Poorly differentiated 25-100%. Not found to be important in multivariate
analysis.[14, 17]
Lympho-vascular Invasion 41% Poor reproducibility.[18]
Incomplete resection 75%[20]
Table 6. Incidence of nodal disease by risk factor
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5.6. The risk of further resection
Oncological resection of colorectal lesions is performed via segmental resection of the affect‐
ed potion of the bowel and its draining lymph node basin. Harvesting these nodes gains lo‐
cal control and definatively stages the disease. It is a major undertaking with considerable
risks. In the case of very low rectal tumours an abdomino-perinal excision of rectum (APER)
results in permanent stoma formation.
In  the  UK at  least,  operative  mortality  has  fallen in  recent  years.  30  day mortality  was
6.8% in 1999, falling to 3.7% in 2009/10.[33,34] Rates from Scandinavia (4.8%)[26] and the
US (3.1%)[27] are broadly similar.  This remains considerably higher than the rate of no‐
dal  disease  in  the  low risk  malignant  polyps.  The 90  day mortality  rate,  considered by
some authors to be a more accurate measure of operative mortality is higher still, is 5.6%
in the UK.[34]
This baseline rate is affected by both tumour and patient factors. Patients over the age of 80
are over ten times more likely to die than those under 50 (15% vs 1.2% 30 day mortality).
[28,33] Comparing ASA1 and ASA4 patients, the odds ratio for death at 30 days is 14.06. Pa‐
tients with rectal tumours do better than those with colonic tumours, though this seems to
be due to high mortality for patients undergoing subtotal or total colectomy. Female sex, af‐
fluence, high volume surgical centres and elective rather than emergency surgery all also
have a beneficial effect.[33]
On  top  of  mortality,  anastomotic  leaks,  wound  complications,  cardiovascular  complica‐
tions, defecatory disorders and the psychological impact of stoma formation must also be
considered when deciding whether  or  not  to  resect.  Morbidity rates  of  up to 35% have
been reported in the past.[15] These seem to affect laparoscopic surgery as much as open
resections, but hospital discharge and return to work occurs sooner following laparoscop‐
ic procedures. [35,36]
A more accurate individualised operative risk can be estimated from risk scoring systems.
CR-POSSUM uses patient and operative parameters to estimate operative risk on an indi‐
vidual basis and has been well validated.[37,38] Cardiopulmonary exercise testing is also
useful in predicting complications and the length of hospital stay. Both these tools can be of
great use to the surgeon and patient when used thoughtfully during surgical planning. [39]
5.7. The special case of rectal tumours
There has been considerable interest in recent years in local resection of early rectal tumours
to avoid stoma formation. This is relevant as malignant polyps in the rectum are a variety of
early rectal tumour. Transanal Endoscopic Microsurgery (TEMS) allows full thickness exci‐
sion of rectal lesions below the peritoneal fold, with excellent rates of local recurrence.[15]
Its ability to harvest local lymph nodes is limited, and as such it is not generally a suitable
second procedure for high risk lesions. It may have a role as secondary procedure for incom‐
pletely removed polyps which otherwise show favourable features. In its guidance the
ACPGBI recommended full classical resection of rectal tumours that show the high risk fea‐
tures described earlier.[40]
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The anatomical location of the draining nodes in rectal lesions has also encouraged more ex‐
tensive use of imaging to predict local nodal metastases. Endoanal Ultrasound and MRI
both have the ability to detect enlarged local nodes; however distinguishing between the
commonly found reactive nodes and metastases can be difficult. Micrometastases have also
been detected in radiologically normal nodes. The use of new contrast agents may improve
accuracy but currently histological examination remains the gold standard for detecting no‐
dal disease. [15]
For locally excised T1 and T2 tumours adjuvant chemoradiotherapy has been used with suc‐
cess to prevent local recurrence if further surgery is not deemed appropriate. The role of ad‐
juvant therapy in malignant polyps is unexplored at this time.
5.8. Calculating the survival advantage
As the nodal status of these patients is unknown prior to surgery, mortality is a composite of
the mortality of those with and without nodal disease. The contribution from each group
will be in proportion to the risk of nodal disease.
cM = R.NM + (1-R).nM
Where cM= Composite mortality
R =Risk of nodal disease
NM =Mortality of those with nodal disease
nM =Mortality of those without nodal disease
The best course of action can be discerned by calculating the difference between cM with
and without surgery. Tables 7-9 contain sample composite survival figures and number
needed to treat at five years for various stages of malignant polyp.
Using this method we can see that for a patient with a Sm3 lesion (25% of nodal disease) and
a predicted operative mortality of 2% there will be an absolute risk reduction of mortality at
5 years of 16% (NNT 6.25) if 5 year survival of node positive patients is 75% and a 4.5% re‐
duction (NNT 21.05) if 5 year survival of node positive patients is 27%. In stage IIIa (75%
five year survival) disease the absolute risk is reduced by 10% (NNT 1), but this disappears
for stage IIIc. There has been considerable debate regarding the need to resect Sm2 lesions.
In this model the benefit from resection disappears once operative mortality reaches 5% for
IIIa lesions and 10% for IIIc lesions. Clearly careful though needs to be given to risk when
choosing to operate on these patients.
Obviously  this  model  makes  no  account  of  operative  morbidity.  For  patients  with  IIIc
disease  and  Sm3  lesions  there  is  a  survival  advantage  to  operating;  however  the  deci‐
sion  to  subject  40  patients  to  major  surgery  to  save  1  life  at  five  years  needs  careful
consideration.
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Patient A Patient B Patient C Patient D
Age 55 55 80 60
Lesion Kikuchi Sm3 Haggit level 1 Kikuchi Sm2 Kikuchi Sm1
Risk of nodal disease 25% <1% 10% 5%
Operative Mortality 1% 1% 10% 5%
Compsite Survival without further
resection 81.00 "/>99% 90.50 95.25
Compsite survival with resection 94.20 99% 88.50 94.00
Survival advantage 13.20 - - -
Table 7. Examples of using composite survival to inform decision making in patients with malignant polyps
6. Conclusion
This problem has been known and debated for over 30 years.[41] As the role of endoscopy
has grown and developed, guidelines have been formulated to help clinicians make benefi‐
cial choices. Unfortunately the small scale and heterogeneity for published work had pre‐
vented any guidelines from gaining universal acceptance. The focus on tumour grade in the
American guidance has been challenged by work from Japan that emphasises the impor‐
tance of quantitative measures of the depth of invasion. Japanese work has also shown lym‐
phatic invasion, vascular invasion and tumour budding to be of high prognostic
significance, but concerns about reproducibility have prevented their universal adoption. It
is also unclear which observed prognostic factors are truly significant and which are co-
founding. None of the prognostic factors identified are highly specific and clinicians must
still make difficult decisions based on the balance of risk.
The solution to this problem will surely come from improved pre-operative staging. En‐
do-anal  ultra  sound and targeted contrast  MRI  have both  shown promise  for  rectal  tu‐
mours.  Sentinel  node  mapping  in  the  colon  has  also  been  investigated  but  remains
experimental. [42]
Until highly accurate pre-operative staging of nodal disease is possible effort must be made
to refine the classification of malignant polyps to identify the truly significant prognostic
factors. It is the opinion of the authors that an individualised prediction model comparing
operative surgical risk and risk of progressive disease should be used to counsel patients re‐
garding future strategies. Creation of a national or international database would facil;itate
better predictive models.
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Risk Of Nodal
Disease/% Operative Survival/ %
99 98 95 90 85
5
No Resectio /% 95.25 95.25 95.25 95.25 95.25
Resection/% 98.45 97.50 94.65 89.90 85.15
Survival Advantage/% 3.20 2.25 - - -
NNT 31.25 44.44 - - -
10
No Resection/% 90.50 90.50 90.50 90.50 90.50
Resection/% 97.90 97.00 94.30 89.80 85.30
Survival Advantage/% 7.40 6.50 3.80 - -
NNT 13.51 15.38 26.32 - -
15
No Resection/% 85.75 85.75 85.75 85.75 85.75
Resection/% 97.35 96.50 93.95 89.70 85.45
Survival Advantage/% 11.60 10.75 8.20 3.95 -
NNT 8.62 9.30 12.20 25.32 -
20
No Resection/% 81.00 81.00 81.00 81.00 81.00
Resection/% 96.80 96.00 93.60 89.60 84.00
Survival Advantage/% 15.80 15.00 12.60 8.60 3.00
NNT 6.33 6.67 7.94 11.63 33.33
25
No Resection/% 76.25 76.25 76.25 76.25 76.25
Resection/% 96.25 95.50 93.25 89.50 85.75
Survival Advantage/% 20.00 19.25 17.00 13.25 9.50
NNT 5.00 5.19 5.88 7.55 10.53
30
No Resection/% 71.50 71.50 71.50 71.50 71.50
Resection/% 95.70 95.00 92.90 89.40 85.90
Survival Advantage/% 24.20 23.50 21.40 17.90 14.40
NNT 0.04 0.04 0.05 0.06 0.07
Table 8. 5 year survival, survival advantage with further resection and number needed to treat if 5 year survival for
node positive patients is 88% after resection.
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Risk Of Nodal
Disease/% Operative Survival/ %
99 98 95 90 85
5
No Resection/% 95.25 95.25 95.25 95.25 95.25
Resection/% 97.80 96.85 94.00 89.25 84.50
Survival Advantage/% 2.55 1.60 - - -
NNT 39.22 62.50 - - -
10
No Resection/% 90.50 90.50 90.50 90.50 90.50
Resection/% 96.60 95.70 93.00 88.50 84.00
Survival Advantage/% 6.10 5.20 2.50 - -
NNT 16.39 19.23 40.00 - -
15
No Resection/% 85.75 85.75 85.75 85.75 85.75
Resection/% 95.40 94.55 92.00 87.75 83.50
Survival Advantage/% 9.65 8.80 6.25 2.00 -
NNT 10.36 11.36 16.00 50.00 -
20
No Resection/% 81.00 81.00 81.00 81.00 81.00
Resection/% 94.20 93.40 91.00 87.00 83.00
Survival Advantage/% 13.20 12.40 10.00 6.00 2.00
NNT 7.58 8.06 10.00 16.67 50.00
25
No Resection/% 76.25 76.25 76.25 76.25 76.25
Resection/% 93.00 92.25 90.00 86.25 82.50
Survival Advantage/% 16.75 16.00 13.75 10.00 6.25
NNT 5.97 6.25 7.27 10.00 16.00
30
No Resection/% 71.50 71.50 71.50 71.50 71.50
Resection/% 91.80 91.10 89.00 85.50 82.00
Survival Advantage/% 20.30 19.60 17.50 14.00 10.50
NNT 4.93 5.10 5.71 7.14 9.52
Table 9. 5 year survival, survival advantage with further resection and number needed to treat if 5 year survival is 75%
after resection.
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Risk Of Nodal
Disease/% Operative Survival/ %
99 98 95 90 85
5
No Resection/% 95.25 95.25 95.25 95.25 95.25
Resection/% 95.30 94.35 91.50 86.75 82.00
Survival Advantage/% 0.05 - - - -
NNT 2000.00 - - - -
10
No Resection/% 90.50 90.50 90.50 90.50 90.50
Resection/% 91.60 90.70 88.00 83.50 79.00
Survival Advantage/% 1.10 0.20 - - -
NNT 90.91 500.00 - - -
15
No Resection/% 85.75 85.75 85.75 85.75 85.75
Resection/% 87.90 87.05 84.50 80.25 76.00
Survival Advantage/% 2.15 1.30 - - -
NNT 46.51 76.92 - - -
20
No Resection/% 81.00 81.00 81.00 81.00 81.00
Resection/% 84.20 83.40 81.00 77.00 73.00
Survival Advantage/% 3.20 2.40 0.00 - -
NNT 31.25 41.67 - - -
25
No Resection/% 76.25 76.25 76.25 76.25 76.25
Resection/% 80.50 79.75 77.50 73.75 70.00
Survival Advantage/% 4.25 3.50 1.25 - -
NNT 23.53 28.57 80.00 - -
30
No Resection/% 71.50 71.50 71.50 71.50 71.50
Resection/% 76.80 76.10 74.00 70.50 67.00
Survival Advantage/% 5.30 4.60 2.50 - -
NNT 18.87 21.74 40.00 - -
Table 10. 5 year survival, survival advantage with further resection and number needed to treat if 5 year survival in
node positive patients is 27% after resection.
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